USPTO Examiner WELCH WILLOW GRACE - Art Unit 3792

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19009232SYSTEMS AND METHODS FOR RHYTHM RECOGNITIONJanuary 2025May 2025Allow400YesNo
18981252SYSTEMS AND METHODS FOR SEIZURE DETECTION AND CLOSED-LOOP NEUROSTIMULATIONDecember 2024December 2025Allow1320YesNo
18385084TRUE ONSET IDENTIFICATIONOctober 2023March 2026Abandon2830YesNo
18230941FEATURE SELECTION AND SENSING OPTIMIZATION FOR ADAPTIVE NEUROMODULATION THERAPYAugust 2023February 2026Allow3110NoNo
17926278CONTROL METHOD FOR A NEUROPROSTHETIC DEVICE FOR THE REDUCTION OF PATHOLOGICAL TREMORSNovember 2022November 2025Abandon3610NoNo
18050751BILATERAL VAGUS NERVE STIMULATIONOctober 2022September 2025Allow3420YesNo
17940793SYSTEM AND METHOD FOR AUTOMATING BEDSIDE INFECTION AUDITS USING MACHINE LEARNINGSeptember 2022October 2025Abandon3801NoNo
17817167SYSTEMS AND METHODS FOR TATTOO REMOVALAugust 2022July 2025Abandon3610NoNo
17870808PHYSIOTHERAPY DEVICE AND METHOD FOR CONTROLLING PHYSIOTHERAPY DEVICEJuly 2022April 2025Allow3310YesNo
17863629METHOD FOR TREATING OR ALLEVIATING BACK PAINJuly 2022January 2026Abandon4220YesNo
17851748IMPLANTABLE BATTERY DEVICE FOR STANDARD COCHLEAR IMPLANTJune 2022August 2025Abandon3820NoNo
17788191SKIN CARE DEVICEJune 2022March 2026Abandon4430NoNo
17786416ELECTROCARDIOGRAM LEAD GUIDE SYSTEM AND METHODJune 2022November 2025Allow4130NoNo
17840447ATRIAL FIBRILLATION DETECTION DEVICE, METHOD, SYSTEM AND STORAGE MEDIUMJune 2022September 2025Abandon3920NoNo
17839095FATIGUE MANAGEMENT & OXYGENATION / HYDRATION OPTIMIZATIONJune 2022April 2025Abandon3410NoNo
17773786HAIR CUTTING DEVICE AND HAIR CUTTING SYSTEMMay 2022April 2025Allow3520YesYes
17722492Wearable Blood Pressure MonitorApril 2022February 2025Abandon3410NoNo
17768386LEARNING DEVICE, LEARNING METHOD, AND MEASUREMENT DEVICEApril 2022February 2025Abandon3510NoNo
17767522MOUTHPIECE-TYPE TREATMENT DEVICEApril 2022March 2025Abandon3510NoNo
17711232WEARABLE SAFETY LASING LIGHT THERAPY DEVICEApril 2022July 2025Abandon3920NoNo
17699592MENTAL AND PHYSICAL CONDITION ESTIMATION SYSTEM, MENTAL AND PHYSICAL CONDITION ESTIMATION METHOD, AND STORAGE MEDIUMMarch 2022February 2025Allow3520YesNo
17696077ELECTRONIC DEVICE AND METHOD OF ESTIMATING BIOINFORMATIONMarch 2022April 2025Allow3720YesNo
17642850NEUROMODULATION OF THE GLOSSOPHARYNGEAL NERVE TO IMPROVE SLEEP DISORDERED BREATHINGMarch 2022June 2025Allow3940YesNo
17686749INSTRUMENT CASSETTE ASSEMBLIES FOR ROBOTIC SURGICAL INSTRUMENTSMarch 2022May 2025Allow3820NoNo
17638816SLEEP MONITORING METHOD AND APPARATUS, SLEEP AID DEVICE AND METHODFebruary 2022January 2025Allow3410YesNo
17583921MACHINE LEARNING TECHNIQUES FOR PARASOMNIA EPISODE MANAGEMENTJanuary 2022February 2026Abandon4840YesNo
17628747Electrical Stimulation Device and MethodJanuary 2022July 2025Abandon4230NoNo
17575630System and Method for Noninvasive Sleep Monitoring and ReportingJanuary 2022October 2025Allow4520NoNo
17645852METHOD FOR ESTIMATING A HEART RATE OR A BREATHING RATEDecember 2021September 2025Abandon4520NoNo
17644318DEVICE FOR MONITORING PHYSIOLOGICAL DATA AND SYSTEM COMPRISING SUCH DEVICEDecember 2021February 2026Allow5040YesYes
17540396SYSTEMS AND METHODS FOR A KINEMATICALLY-CONTROLLED REMOTE CENTER MANIPULATORDecember 2021February 2025Allow3920YesNo
17614572MEDICAL TOOL CONTROL SYSTEM, CONTROLLER, AND NON-TRANSITORY COMPUTER READABLE STORAGENovember 2021December 2024Abandon3710NoNo
17288580WEARABLE SURGICAL ROBOT ARMNovember 2021November 2024Abandon4310NoNo
17515583FLASH LED AND HEART RATE MONITOR LED INTEGRATION AND RELATED DEVICES AND METHODSNovember 2021August 2024Abandon3310NoNo
17607600INTELLIGENT VECTOR ELECTRODE FOR A PACEMAKER OR AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOROctober 2021September 2025Abandon4721NoNo
17500969Method for Health Detection Supportive Devices and SystemOctober 2021November 2024Abandon3810NoNo
17489413SYSTEMS AND METHODS FOR DETECTING ATRIAL TACHYARRHYTHMIASeptember 2021January 2026Allow5250YesNo
17486188IMPLANTABLE NEUROSTIMULATOR-IMPLEMENTED METHOD FOR MANAGING BRADYCARDIA THROUGH VAGUS NERVE STIMULATIONSeptember 2021March 2025Allow4130YesNo
17598116INTEGRATED HEALTH PLATFORMSeptember 2021November 2024Abandon3810NoNo
17484715BIO-INFORMATION MEASURING APPARATUS AND BIO-INFORMATION MEASURING METHODSeptember 2021March 2025Allow4230YesNo
17482105INDIVIDUALLY WEARABLE ELECTROMAGNITIC SENSING (iwEMS) SYSTEM AND METHOD FOR NON-INVASIVE ASSESSMENT OF TISSUE BLOOD AND OXYGEN CONTENTSeptember 2021April 2024Allow3110NoNo
17478838PHYSIOLOGICAL PARAMETER MONITORING DEVICE AND METHODSeptember 2021January 2025Abandon4020NoNo
17310831METHOD AND APPARATUS TO MODIFY THE CORNEA USING ELECTROCHEMISTRYAugust 2021September 2025Abandon4941YesNo
17350618METHOD AND ELECTRONIC APPARATUS FOR PROVIDING CLASSIFICATION DATA OF ELECTROCARDIOGRAM SIGNALSJune 2021March 2026Abandon5760YesNo
17342652SECURITY AND AUTHENTICATION ACCESS FOR MEDICAL IMPLANTSJune 2021July 2025Abandon4940YesNo
17293020SURGICAL INSTRUMENT WITH SENSOR ALIGNED CABLE GUIDEMay 2021June 2025Allow4930YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WELCH, WILLOW GRACE.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
11.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WELCH, WILLOW GRACE - Prosecution Strategy Guide

Executive Summary

Examiner WELCH, WILLOW GRACE works in Art Unit 3792 and has examined 18 patent applications in our dataset. With an allowance rate of 38.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner WELCH, WILLOW GRACE's allowance rate of 38.9% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WELCH, WILLOW GRACE receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WELCH, WILLOW GRACE is 43 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +55.6% benefit to allowance rate for applications examined by WELCH, WILLOW GRACE. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.7% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 4% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 23% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 100% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 50% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.